论文部分内容阅读
目的:探讨培哚普利对轻中度原发性高血压(EH)患者血管炎性因子和内皮功能的影响。方法:100例EH患者随机分为培哚普利治疗组(培哚普利组,50例)和常规治疗组(常规组,50例),两组患者在入院后次日凌晨分别空腹采肘静脉血,测定血浆高敏C反应蛋白(hs-CRP)、纤维蛋白原(FIB-C)、内皮素1(ET-1)及一氧化氮(NO)的含量;另选择健康体检者50例作对照组,培哚普利组治疗4周后复查上述指标,与对照组进行比较。结果:培哚普利组和常规组治疗前血浆hs-CRP、FIB-C及ET-1水平较对照组明显增高,NO下降(均P<0.05);治疗4周后,常规组血浆hs-CRP、FIB-C、ET-1与NO水平较治疗前无显著性变化,培哚普利组血浆hs-CRP、FIB-C与ET-1水平均较治疗前下降(均P<0.01),NO升高(P<0.05)。结论:培哚普利可以抑制EH患者血管炎症反应,改善血管内皮功能。
Objective: To investigate the effect of perindopril on vascular inflammatory factor and endothelial function in patients with mild to moderate essential hypertension (EH). Methods: One hundred patients with EH were randomly divided into two groups: perindopril group (50 cases perindopril group) and conventional treatment group (n = 50). Two groups of patients were on the next morning after fasting Venous blood was collected to determine the content of plasma hs-CRP, FIB-C, ET-1 and NO. 50 healthy volunteers Control group, perindopril group after 4 weeks of treatment to review the above indicators, compared with the control group. Results: The levels of hs-CRP, FIB-C and ET-1 in perindopril group and conventional group before treatment were significantly higher than those in control group (P <0.05). After 4 weeks of treatment, The levels of plasma hs-CRP, FIB-C and ET-1 in perindopril group were significantly lower than those before treatment (all P <0.01) NO increased (P <0.05). Conclusion: Perindopril can inhibit vascular inflammation and improve endothelial function in patients with EH.